Specificity enhancing reagent for robust SARS-CoV-2 serology testing

用于稳健 SARS-CoV-2 血清学检测的特异性增强试剂

• 批准号: 98088
• 金额: $ 32.36万
• 依托单位: APIS ASSAY TECHNOLOGIES LTD.
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=98088
• 关键词: Specificity; enhancing; reagent; robust; SARS

As part of the COVID-19 pandemic response, measuring the presence of an immune response to SARS-CoV-2 will be widely used to determine whether individuals have acquired immunity. Antibodies bind to specific sites on viral proteins. Measuring the presence of antibodies that can bind SARS-CoV-2 proteins in the plasma and serum can provide information about whether an individual is immune. This is a critical testing approach for monitoring the effectiveness of vaccines during clinical trials and after launch.The challenge is that common coronaviruses that cause the common cold are widespread in the population and have similar viral protein structures to SARS-CoV-2\. This means that for some individuals, when they are tested for immunity, their existing antibodies against common coronavirus proteins may bind SARS-CoV-2 proteins, generating a measurable signal and an incorrect result. This individual will be told that they have immunity against SARS-CoV-2 when they are not immune and may expose themselves to a higher risk in their daily activities. Ultimately, this will lead to a higher rate of avoidable infections and associated hospitalisations, with wider economic and social impacts.Apis Assay Technologies Ltd. aims to develop a novel, innovative reagent to block common coronavirus antibodies from binding SARS-CoV-2 viral protein. This means that any measurable signal generated from antibodies binding SARS-CoV-2 proteins will be due to the presence of SARS-CoV-2 antibodies, therefore drastically reducing the likelihood of an incorrect result. This innovative reagent has potential to address a large global vaccine monitoring market with high return on investment. Apis Assay Technologies Ltd. plans two commercial product launches - **1)** a stand-alone reagent that can be used to adapt and improve performance of any compatible 3rd party immunity test; **2)** a highly competitive immunity test with the reagent integrated. For maximum penetration of the market, Apis Assay Technologies Ltd. strives to fast-track product development to facilitate early access to these products.

作为COVID-19大流行应对措施的一部分，测量对SARS-CoV-2的免疫反应的存在将被广泛用于确定个体是否获得免疫力。抗体与病毒蛋白质上的特定位点结合。测量血浆和血清中能够结合SARS-CoV-2蛋白的抗体的存在可以提供关于个体是否具有免疫力的信息。这是在临床试验期间和上市后监测疫苗有效性的关键测试方法，挑战在于导致普通感冒的常见冠状病毒在人群中广泛传播，并且与SARS-CoV-2\具有相似的病毒蛋白结构。这意味着，对于某些个体来说，当他们接受免疫力测试时，他们现有的针对普通冠状病毒蛋白的抗体可能会结合SARS-CoV-2蛋白，产生可测量的信号和错误的结果。该个体将被告知他们对SARS-CoV-2具有免疫力，而他们没有免疫力，并且可能在日常活动中暴露于更高的风险中。最终，这将导致更高的可避免感染率和相关住院率，并产生更广泛的经济和社会影响。Apis Assay Technologies Ltd.旨在开发一种新型的创新试剂，以阻止常见的冠状病毒抗体与SARS-CoV-2病毒蛋白结合。这意味着结合SARS-CoV-2蛋白的抗体产生的任何可测量信号都将是由于SARS-CoV-2抗体的存在，因此大大降低了错误结果的可能性。这种创新的试剂有潜力解决全球疫苗监测市场的巨大需求，并具有高投资回报率。Apis Assay Technologies Ltd.计划推出两种商业产品- **1）** 一种独立试剂，可用于调整和提高任何兼容的第三方免疫检测的性能; **2）** 一种集成试剂的高度竞争性免疫检测。为了最大限度地渗透市场，Apis Assay Technologies Ltd.致力于快速跟踪产品开发，以促进抢先体验这些产品。